Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

IEP INVEST Stock Was Up By 9.8% Today

Loading stream...

(VIANEWS) - The Market ended the session with IEP INVEST (IEP.BR) jumping 9.8% to €5.60 on Monday while BEL 20 rose 0.44% to €3,305.14.

IEP INVEST's last close was €5.10, 13.56% below its 52-week high of €5.90.

About IEP INVEST

Iep Invest, NV is an investment firm specializing in investments in and loans to real estate companies. The firm previously operated as manufacturing group. It was formerly known as Punch International nv and changed its name to Iep Invest, NV in May 2014. Iep Invest, NV was founded in 1982 and is based in Antwerp, Belgium.

Earnings Per Share

As for profitability, IEP INVEST has a trailing twelve months EPS of €-0.22.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -2.4%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Oct 3, 2022, the estimated forward annual dividend rate is 5 and the estimated forward annual dividend yield is 87.72%.

More news about IEP INVEST (IEP.BR).

Categories

stockMarket

Tags

Market-Close NowStock PriceIEP.BRClosesStock Market NowEnd of DayPrice UpMarket CloseStock Price UpIEP INVESTStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com